Drug Trial Radar · NCT01188928
LEO 80185 in the Treatment of Psoriasis Vulgaris on the Non-scalp Regions of the Body (Trunk and/or Limbs)
Last checked: Nov 19, 2026Latest source record: Mar 10, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,152
Actual
Start
Sep 2010
Primary completion
Mar 2011
Study completion Mar 2011
Sponsor
- Lead sponsor
- LEO PharmaIndustry
- Sponsor type
- Industry
- First posted
- Aug 26, 2010
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Double (participant, investigator)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to compare the efficacy and safety of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension with the active components when used individually as monotherapy in the topical suspension vehicle (betamethasone dipropionate in the topical suspension vehicle, calcipotriol in the topical suspension vehicle) and with the topical suspension vehicle alone in the treatment of psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs) in a large phase 3 study. This comparison will ensure a more informed assessment of the benefit/risk ratio of Calcipotriol 50 Mcg/g Plus Betamethasone 0.5 mg/g (as Dipropionate) Topical Suspension while also establishing the optimal treatment duration in psoriasis vulgaris on the non-scalp regions of the body (trunk and/or limbs).
Conditions
- Psoriasis Vulgaris
Interventions
Calcipotriol plus betamethasoneDrug
Topical suspension once daily for up to 8 weeks.
Betamethasone-17,21-dipropionateDrug
Topical suspension once daily for up to 8 weeks.
CalcipotrieneDrug
Topical suspension once daily for up to 8 weeks.
Topical suspension vehicleDrug
Topical suspension once daily for up to 8 weeks.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 4Time frame: 4 weeks
- Controlled Disease According to the Investigator's Global Assessment of Disease Severity (IGA) at Weeks 8Time frame: week 8
Locations
59 sites in 1 country. Site status is shown where the registry gives one.
Horizon Research Group, Inc
Mobile, Alabama
Burke Pharmaceutical Research
Hot Springs, Arkansas
Advanced Clinical Research Institute
Anaheim, California
DBA Torrance Clinical Research
Lomita, California
Dermatology Specialists, Inc.
Oceanside, California
Skin Surgery Medical Group, Inc.
San Diego, California
Walter Nahm, MD, Ph.D., Inc
San Diego, California
Coastal Medical Research Group, Inc.
San Luis Obispo, California
Clinical Science Institute
Santa Monica, California
Dermatology Research Centers
Santa Monica, California
Colorado Medical Research Center, Inc.
Denver, Colorado
Horizons Clinical Research Center, LLC
Denver, Colorado
Visions Clinical Research
Boynton Beach, Florida
Dermatology Associates and Research
Coral Gables, Florida
North Florida Dermatology Associates, PA
Jacksonville, Florida
International Dermatology Research, Inc.
Miami, Florida
Ameriderm Research
Ormond Beach, Florida
Palm Beach Research Center
West Palm Beach, Florida
Atlanta Dermatology, Vein & Research Center
Alpharetta, Georgia
Peachtree Dermatology Associates
Atlanta, Georgia
Dermatologic Surgery Specialists, PC
Macon, Georgia
Gwinnett Clinical Research Center, Inc
Snellville, Georgia
Altman Dermatology Associates
Arlington Hts, Illinois
Glazer Dermatology
Buffalo Grove, Illinois
Deaconess Clinic, Inc.
Evansville, Indiana
Hudson Dermatology
Evansville, Indiana
Dawes Fretzin Clinical Research Group
Indianapolis, Indiana
Indiana Clinical Trials Center
Plainfield, Indiana
Dermatology Specialists
Louisville, Kentucky
Owensboro Dermatology Associates
Owensboro, Kentucky
Lawrence J. Green, MD, LLC
Rockville, Maryland
David Fivenson, MD Dermatology, PLC
Ann Arbor, Michigan
Great Lakes Research Group, Inc
Bay City, Michigan
Michigan Center for Research Corp.,
Clinton Township, Michigan
Henry Ford Health System
Detroit, Michigan
Hamzavi Dermatology
Fort Gratiot, Michigan
Somerset Skin Centre
Troy, Michigan
Grekin Skin Institute
Warren, Michigan
Minnesota Clinical Study Center
Fridley, Minnesota
Karl G. Heine, M. D. Dermatology
Henderson, Nevada
Showing 40 of 59 sites, US sites first. The full list is on the registry record.
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.